![Barry Gallagher](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Profilo
Barry Gallagher served as the Chief Executive Officer at Drive from 1992 to 2018.
Precedenti posizioni note di Barry Gallagher
Società | Posizione | Fine |
---|---|---|
Drive
![]() Drive Miscellaneous Commercial ServicesCommercial Services Drive is a non-profit LLC that focuses on discovering and developing antiviral drugs for emerging infections, pandemic threats, and biodefense. The non-profit company is based in Nantgarw, UK. The British company operates like an early stage biotechnology company and applies focus and industry development expertise to efficiently translate discoveries to address viruses of concern. The company is unique in that it brings industry expertise to the assets of a leading research university to develop potential antiviral drugs to a de-risked value inflection point that substantially increases the probability of the potential drug being licensed by industry and developed for the ultimate benefit of the public. The company was founded in 1983. Rhian Jones has been the CEO of the company since 2018. | Amministratore Delegato | 18/09/2018 |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
Aziende private | 1 |
---|---|
Drive
![]() Drive Miscellaneous Commercial ServicesCommercial Services Drive is a non-profit LLC that focuses on discovering and developing antiviral drugs for emerging infections, pandemic threats, and biodefense. The non-profit company is based in Nantgarw, UK. The British company operates like an early stage biotechnology company and applies focus and industry development expertise to efficiently translate discoveries to address viruses of concern. The company is unique in that it brings industry expertise to the assets of a leading research university to develop potential antiviral drugs to a de-risked value inflection point that substantially increases the probability of the potential drug being licensed by industry and developed for the ultimate benefit of the public. The company was founded in 1983. Rhian Jones has been the CEO of the company since 2018. | Commercial Services |
- Borsa valori
- Insiders
- Barry Gallagher